NKTR insider transactions
Nektar Therapeutics (NKTR) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
NKTR insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Nektar Therapeutics, latest first. Follow anyone to get their next filing.
- Roy A WhitfieldDirector-$17.1K
- R Scott GreerDirector
- Robert ChessDirector-$824K
- Diana BrainardDirector, since November 2021
- Jeffrey Robert AjerDirector-$81.4K
- Jonathan ZalevskyChief R&D Officer-$2.78M
- Howard W RobinPresident & CEO, Director-$13.2M
- Linda M RubinsteinInterim CFO, since May 2026
- Mark Andrew WilsonChief Legal Officer-$583K
- Deep Track Capital, LP10% owner, since March 2024-$99.6K
- Myriam CuretDirector-$81.4K
- Sandra A. GardinerOfficer, since April 2023
- Jillian B. ThomsenOfficer-$2.06M
- Karin EasthamDirector-$76.8K
- John NorthcottOfficer-$692K
- Gil M LabrucherieOfficer-$3.92M
Recent Form 3, 4, and 5 filings for NKTR
- Director Whitfield Roy A was granted 2,000 shares, increasing direct ownership by 14% to 16,417 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Director Greer R Scott was granted 2,000 shares, increasing direct ownership by 10% to 22,239 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Director Brainard Diana was granted 2,000 shares, increasing direct ownership by 105% to 3,904 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Director Chess Robert was granted 2,000 shares, increasing direct ownership by 12% to 19,019 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Director Ajer Jeffrey Robert was granted 2,000 shares, increasing direct ownership by 88% to 4,277 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $13,388 worth of shares (186 units at $71.98), decreasing direct ownership by 2% to 9,570 units (SEC Form 4) (withholding obligation)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $30,088 worth of shares (418 units at $71.98), decreasing direct ownership by 0.76% to 54,627 units (SEC Form 4) to satisfy tax liability4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 4 filed by Chief R&D Officer Zalevsky Jonathan4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 4 filed by President & CEO Robin Howard W4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $397,670 worth of shares (5,681 units at $70.00) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 9,756 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $1,215,056 worth of shares (20,000 units at $60.75) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 55,045 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $336,212 worth of shares (5,538 units at $60.71) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 15,437 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 3 filed by new insider Rubinstein Linda M3 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $13,036 worth of shares (199 units at $65.51), decreasing direct ownership by 0.94% to 20,975 units (SEC Form 4) (withholding tax)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $29,086 worth of shares (444 units at $65.51), decreasing direct ownership by 0.59% to 75,045 units (SEC Form 4) (tax withholding)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $13,140 worth of shares (180 units at $73.00), decreasing direct ownership by 0.84% to 21,174 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $30,879 worth of shares (423 units at $73.00), decreasing direct ownership by 0.56% to 75,489 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $137,936 worth of shares (3,867 units at $35.67), decreasing direct ownership by 15% to 21,354 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan was granted 6,250 shares, increasing direct ownership by 33% to 25,221 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W was granted 21,667 shares, increasing direct ownership by 40% to 75,912 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan was granted 2,666 shares and sold $62,802 worth of shares (1,157 units at $54.28), increasing direct ownership by 9% to 18,971 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief Legal Officer Wilson Mark Andrew sold $34,196 worth of shares (630 units at $54.28) and was granted 1,903 shares, increasing direct ownership by 6% to 21,585 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W was granted 7,110 shares and sold $119,796 worth of shares (2,207 units at $54.28), increasing direct ownership by 10% to 54,245 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 4 filed by Director Whitfield Roy A4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 4 filed by Director Greer R Scott4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 4 filed by Director Chess Robert4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 4 filed by Director Brainard Diana4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 4 filed by Director Ajer Jeffrey Robert4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $311,214 worth of shares (6,666 units at $46.69), decreasing direct ownership by 12% to 49,342 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $57,693 worth of shares (1,721 units at $33.52), decreasing direct ownership by 9% to 17,462 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $430,959 worth of shares (11,832 units at $36.42), decreasing direct ownership by 17% to 56,008 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $14,598 worth of shares (485 units at $30.10), decreasing direct ownership by 2% to 19,183 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $45,240 worth of shares (1,500 units at $30.16), decreasing direct ownership by 2% to 67,840 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $19,278 worth of shares (725 units at $26.59), decreasing direct ownership by 4% to 19,668 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief Legal Officer Wilson Mark Andrew sold $17,975 worth of shares (676 units at $26.59), decreasing direct ownership by 3% to 20,312 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $41,826 worth of shares (1,573 units at $26.59), decreasing direct ownership by 2% to 69,340 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $7,177 worth of shares (10,712 units at $0.67), decreasing direct ownership by 3% to 305,892 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief Legal Officer Wilson Mark Andrew sold $6,697 worth of shares (9,996 units at $0.67), decreasing direct ownership by 3% to 314,296 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $15,549 worth of shares (23,208 units at $0.67), decreasing direct ownership by 2% to 1,063,693 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $10,403 worth of shares (10,300 units at $1.01), decreasing direct ownership by 3% to 316,604 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief Legal Officer Wilson Mark Andrew sold $11,150 worth of shares (11,040 units at $1.01), decreasing direct ownership by 3% to 324,292 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $24,012 worth of shares (23,774 units at $1.01), decreasing direct ownership by 2% to 1,086,901 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 5 filed by Whitfield Roy A5 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 5 filed by Greer R Scott5 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 5 filed by Chess Robert5 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 5 filed by Brainard Diana5 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SEC Form 5 filed by Ajer Jeffrey Robert5 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief Legal Officer Wilson Mark Andrew sold $44,800 worth of shares (49,962 units at $0.90), decreasing direct ownership by 13% to 335,332 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $48,048 worth of shares (51,115 units at $0.94), decreasing direct ownership by 14% to 326,904 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $131,650 worth of shares (132,030 units at $1.00), decreasing direct ownership by 11% to 1,110,675 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan was granted 135,000 shares, increasing direct ownership by 56% to 378,019 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief Legal Officer Wilson Mark Andrew was granted 165,938 shares, increasing direct ownership by 76% to 385,294 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W was granted 410,625 shares, increasing direct ownership by 49% to 1,242,705 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $7,863 worth of shares (7,785 units at $1.01), decreasing direct ownership by 3% to 243,019 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief Legal Officer Wilson Mark Andrew sold $6,471 worth of shares (6,407 units at $1.01), decreasing direct ownership by 3% to 218,856 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $16,441 worth of shares (16,278 units at $1.01), decreasing direct ownership by 2% to 832,080 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief R&D Officer Zalevsky Jonathan sold $8,788 worth of shares (6,866 units at $1.28), decreasing direct ownership by 3% to 250,804 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Chief Legal Officer Wilson Mark Andrew sold $7,233 worth of shares (5,651 units at $1.28), decreasing direct ownership by 2% to 225,263 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- President & CEO Robin Howard W sold $19,048 worth of shares (14,881 units at $1.28), decreasing direct ownership by 2% to 848,358 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- Director Chess Robert sold $23,400 worth of shares (19,500 units at $1.20), decreasing direct ownership by 7% to 255,273 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)